Stoke Therapeutics, Inc. is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen ...
Canaccord raised the firm’s price target on Stoke Therapeutics (STOK) to $28 from $24 and keeps a Buy rating on the shares. The firm said they ...
Stoke Therapeutics ( ($STOK) ) has released its Q3 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...
Software & Services revenue grows 41% to $305 million Annual recurring revenue grows 41% to $1.3 billion Net loss was $2 million, with non-GAAP net income of $98 million and Adjusted EBITDA of $177 ...
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal ...
Stoke Therapeutics, Inc. (NASDAQ:STOK) is one of the Hot Growth Stocks to Invest in Now. On October 10, Ananda Ghosh from H.C. Wainwright reiterated a Buy rating on Stoke Therapeutics, Inc.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and ...
Detailed price information for Stoke Therapeutics Inc (STOK-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback